HC Wainwright Has Bearish Estimate for ENLV FY2025 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Stock analysts at HC Wainwright cut their FY2025 earnings per share estimates for Enlivex Therapeutics in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.59) per share for the year, down from their previous estimate of ($0.58). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a research note on Monday, March 3rd.

Enlivex Therapeutics Price Performance

NASDAQ:ENLV opened at $1.05 on Wednesday. The firm has a market capitalization of $22.48 million, a P/E ratio of -1.07 and a beta of 1.11. The business has a 50 day simple moving average of $1.10 and a 200 day simple moving average of $1.24. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.59.

Institutional Investors Weigh In On Enlivex Therapeutics

Large investors have recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new position in shares of Enlivex Therapeutics during the fourth quarter worth approximately $26,000. Renaissance Technologies LLC raised its stake in Enlivex Therapeutics by 112.6% during the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after acquiring an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in Enlivex Therapeutics during the 4th quarter worth $742,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.